These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

242 related articles for article (PubMed ID: 11487536)

  • 1. A randomized placebo-controlled trial of a humanized monoclonal antibody to alpha4 integrin in active Crohn's disease.
    Gordon FH; Lai CW; Hamilton MI; Allison MC; Srivastava ED; Fouweather MG; Donoghue S; Greenlees C; Subhani J; Amlot PL; Pounder RE
    Gastroenterology; 2001 Aug; 121(2):268-74. PubMed ID: 11487536
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Natalizumab for induction of remission in Crohn's disease.
    MacDonald JK; McDonald JW
    Cochrane Database Syst Rev; 2007 Jan; (1):CD006097. PubMed ID: 17253580
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Natalizumab for induction of remission in Crohn's disease.
    Macdonald JK; McDonald JW
    Cochrane Database Syst Rev; 2006 Jul; (3):CD006097. PubMed ID: 16856112
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Natalizumab for active Crohn's disease.
    Ghosh S; Goldin E; Gordon FH; Malchow HA; Rask-Madsen J; Rutgeerts P; Vyhnálek P; Zádorová Z; Palmer T; Donoghue S;
    N Engl J Med; 2003 Jan; 348(1):24-32. PubMed ID: 12510039
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Safety and tolerability of concurrent natalizumab treatment for patients with Crohn's disease not in remission while receiving infliximab.
    Sands BE; Kozarek R; Spainhour J; Barish CF; Becker S; Goldberg L; Katz S; Goldblum R; Harrigan R; Hilton D; Hanauer SB
    Inflamm Bowel Dis; 2007 Jan; 13(1):2-11. PubMed ID: 17206633
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Natalizumab for the treatment of active Crohn's disease: results of the ENCORE Trial.
    Targan SR; Feagan BG; Fedorak RN; Lashner BA; Panaccione R; Present DH; Spehlmann ME; Rutgeerts PJ; Tulassay Z; Volfova M; Wolf DC; Hernandez C; Bornstein J; Sandborn WJ;
    Gastroenterology; 2007 May; 132(5):1672-83. PubMed ID: 17484865
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Natalizumab induction and maintenance therapy for Crohn's disease.
    Sandborn WJ; Colombel JF; Enns R; Feagan BG; Hanauer SB; Lawrance IC; Panaccione R; Sanders M; Schreiber S; Targan S; van Deventer S; Goldblum R; Despain D; Hogge GS; Rutgeerts P; ;
    N Engl J Med; 2005 Nov; 353(18):1912-25. PubMed ID: 16267322
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A pilot randomized trial of a human anti-interleukin-6 receptor monoclonal antibody in active Crohn's disease.
    Ito H; Takazoe M; Fukuda Y; Hibi T; Kusugami K; Andoh A; Matsumoto T; Yamamura T; Azuma J; Nishimoto N; Yoshizaki K; Shimoyama T; Kishimoto T
    Gastroenterology; 2004 Apr; 126(4):989-96; discussion 947. PubMed ID: 15057738
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Anti-IL-12/23p40 antibodies for induction of remission in Crohn's disease.
    Khanna R; Preiss JC; MacDonald JK; Timmer A
    Cochrane Database Syst Rev; 2015 May; (5):CD007572. PubMed ID: 25942580
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Natalizumab: pharmacology, clinical efficacy and safety in the treatment of patients with Crohn's disease.
    Ko HH; Bressler B
    Expert Rev Gastroenterol Hepatol; 2007 Oct; 1(1):29-39. PubMed ID: 19072431
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Treatment of active Crohn's disease with MLN0002, a humanized antibody to the alpha4beta7 integrin.
    Feagan BG; Greenberg GR; Wild G; Fedorak RN; Paré P; McDonald JW; Cohen A; Bitton A; Baker J; Dubé R; Landau SB; Vandervoort MK; Parikh A
    Clin Gastroenterol Hepatol; 2008 Dec; 6(12):1370-7. PubMed ID: 18829392
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A pilot study of treatment of active ulcerative colitis with natalizumab, a humanized monoclonal antibody to alpha-4 integrin.
    Gordon FH; Hamilton MI; Donoghue S; Greenlees C; Palmer T; Rowley-Jones D; Dhillon AP; Amlot PL; Pounder RE
    Aliment Pharmacol Ther; 2002 Apr; 16(4):699-705. PubMed ID: 11929387
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Novel treatment options for inflammatory bowel disease: targeting alpha 4 integrin.
    Lanzarotto F; Carpani M; Chaudhary R; Ghosh S
    Drugs; 2006; 66(9):1179-89. PubMed ID: 16827596
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Immunotoxicity profile of natalizumab.
    Wehner NG; Gasper C; Shopp G; Nelson J; Draper K; Parker S; Clarke J
    J Immunotoxicol; 2009 Jun; 6(2):115-29. PubMed ID: 19589098
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Natalizumab: AN 100226, anti-4alpha integrin monoclonal antibody.
    Drugs R D; 2004; 5(2):102-7. PubMed ID: 15293871
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A Randomized, Double-Blind, Placebo-Controlled Phase 2 Study of Brodalumab in Patients With Moderate-to-Severe Crohn's Disease.
    Targan SR; Feagan B; Vermeire S; Panaccione R; Melmed GY; Landers C; Li D; Russell C; Newmark R; Zhang N; Chon Y; Hsu YH; Lin SL; Klekotka P
    Am J Gastroenterol; 2016 Nov; 111(11):1599-1607. PubMed ID: 27481309
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Natalizumab for the treatment of Crohn's disease.
    Bickston SJ; Muniyappa K
    Expert Rev Clin Immunol; 2010 Jul; 6(4):513-9. PubMed ID: 20594122
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A randomized, double-blind, placebo-controlled trial of CDP571, a humanized monoclonal antibody to tumour necrosis factor-alpha, in patients with corticosteroid-dependent Crohn's disease.
    Feagan BG; Sandborn WJ; Baker JP; Cominelli F; Sutherland LR; Elson CO; Salzberg BA; Archambault A; Bernstein CN; Lichtenstein GR; Heath PK; Cameron S; Hanauer SB
    Aliment Pharmacol Ther; 2005 Feb; 21(4):373-84. PubMed ID: 15709987
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Natalizumab therapy for moderate to severe Crohn disease in adolescents.
    Hyams JS; Wilson DC; Thomas A; Heuschkel R; Mitton S; Mitchell B; Daniels R; Libonati MA; Zanker S; Kugathasan S;
    J Pediatr Gastroenterol Nutr; 2007 Feb; 44(2):185-91. PubMed ID: 17255829
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Randomized multicenter trial of natalizumab in acute MS relapses: clinical and MRI effects.
    O'Connor PW; Goodman A; Willmer-Hulme AJ; Libonati MA; Metz L; Murray RS; Sheremata WA; Vollmer TL; Stone LA;
    Neurology; 2004 Jun; 62(11):2038-43. PubMed ID: 15184611
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.